Study details
Enrolling now
Pregabalin Plus Lofexidine for Opioid Withdrawal
University of Pennsylvania
NCT IDNCT05995535ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 2.7 years
Ages
18+
Locations
2 sites in MD, PA
Why this study is shown
Actively enrollingPHASE2
What this study is about
This trial is testing whether lofexidine plus pregabalin helps manage opioid withdrawal symptoms in adults. Participants will receive either lofexidine/pregabalin or a placebo, and may be offered extended-release injectable naltrexone after completing the withdrawal period.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LFX/PGB
- 2.Take LFX/PLA-PGB
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Psychiatry / Mental Health